NIH Study Finds Tecovirimat Was Safe but Did Not Improve Mpox Resolution or Pain
December 10, 2024
December 10, 2024
WASHINGTON, Dec. 10 -- The U.S. Department of Health and Human Services' National Institutes of Health issued the following news release:
Study Examined Tecovirimat in Countries Affected by Global Clade II Mpox Outbreak.
The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the inter . . .
Study Examined Tecovirimat in Countries Affected by Global Clade II Mpox Outbreak.
The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the inter . . .